Pharma is starting to use real-world evidence to get a more accurate picture of how drugs fare outside a clinical setting – but it needs to stop being a new concept and start being an integral part of operations
Open to pharma sales
representatives and sales managers, candidates in this prominent industry competition
are both nominated and judged by healthcare professionals. The PharmaTimes Sales
Awards therefore delivers truly
meaningful recognition for pharma sales professionals, from the people who
matter most: their customers.
Clinical researchers in the
Americas: you've got until February 8 to register to take part in this prestigious
competition that offers a unique career development opportunity. PharmaTimes Clinical Researcher of
the Year – The Americas is open for entry!
Cost regulators in Scotland have approved NHS funding for four new medicines, expanding treatment options for lung cancer, iron excess, hepatitis C and chronic pain, but Janssen's Darzalex was rejected for multiple myeloma.
AstraZeneca has expanded a late-stage trial currently assessing a potential new immuno-oncology (IO) therapy combination for the first-line treatment of non-small cell lung cancer (NSCLC), to include extra endpoints for both the combo and monotherapy.
The National Institute for Health Research Efficacy and Mechanism Evaluation (EME) Programme is funding a new £1.5 million trial testing a combination of therapies to prevent rapture in patients with brittle bone disease.